Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma
Metrics: PDF 1465 views | HTML 1588 views | ?
Scott A. Ezell1, Suping Wang1, Teeru Bihani1, Zhongwu Lai1, Shaun E. Grosskurth1, Suprawee Tepsuporn1, Barry R. Davies2, Dennis Huszar1 and Kate F. Byth1
1 AstraZeneca Oncology, Waltham, Massachusetts, MA, USA
2 AstraZeneca Oncology, Macclesfield, Cheshire, UK
Kate F. Byth, email:
Keywords: mTOR, DLBCL, AKT, Ibrutinib, S6K1
Received: July 15, 2015 Accepted: January 19, 2016 Published: January 27, 2016
Agents that target components of the PI3K/AKT/mTOR pathway are under investigation for the treatment of diffuse large B cell lymphoma (DLBCL). Given the highly heterogeneous nature of DLBCL, it is not clear whether all subtypes of DLBCL will be susceptible to PI3K pathway inhibition, or which kinase within this pathway is the most favorable target. Pharmacological profiling of a panel of DLBCL cell lines revealed a subset of DLBCL that was resistant to AKT inhibition. Strikingly, sensitivity to AKT inhibitors correlated with the ability of these inhibitors to block phosphorylation of S6K1 and ribosomal protein S6. Cell lines resistant to AKT inhibition activated S6K1 independent of AKT either through upregulation of PIM2 or through activation by B cell receptor (BCR) signaling components. Finally, combined inhibition of AKT and BTK, PIM2, or S6K1 proved to be an effective strategy to overcome resistance to AKT inhibition in DLBCL.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.